{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:57:25Z","timestamp":1791464245656,"version":"4.3.4"},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>To investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to secondary cytoreductive surgery (SCS) without neoadjuvant chemotherapy has a benefit on progression-free survival (PFS), as opposed to SCS alone in patients with platinum-sensitive recurrent epithelial ovarian cancer (platinum-free interval, &gt;6 months).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>\n              This was a multicenter randomized phase III study. Random assignment was performed at the time of surgery in cases with residual tumor \u22640.25 cm. HIPEC with cisplatin (CDDP) 75 mg\/m\n              <jats:sup>2<\/jats:sup>\n              for 60 minutes at 41.5\u00b0C was administered at the end of surgery in the experimental arm. Both groups received postoperative platinum-based chemotherapy. The primary end point was PFS. The safety profile and postrecurrence survival (PRS) were the secondary end points.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>A total of 167 patients underwent random assignment, 82 patients to SCS plus HIPEC (experimental arm) and 85 to SCS alone (control arm). The median follow-up was 83 months (IQR, 64-102). The median PFS was 23 months (95% CI, 17 to 29) in the group that underwent surgery alone and 25 months (95% CI, 18 to 32) in the group that underwent cytoreductive surgery with HIPEC. The probability of PRS at 5 years was 61.6% (95% CI, 50.8 to 72.4) in the SCS group and 75.9% (95% CI, 66.5 to 85.3) in the SCS plus HIPEC group. The incidence of postoperative adverse events of any grade was similar between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The addition of HIPEC to complete or nearly complete primary SCS did not confer a benefit in terms of PFS in patients with platinum-sensitive peritoneal recurrence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/jco.24.00686","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T20:59:13Z","timestamp":1732222753000},"page":"852-860","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":42,"title":["Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18)"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct01539785","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":true,"given":"Anna","family":"Fagotti","sequence":"first","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-0106","authenticated-orcid":true,"given":"Barbara","family":"Costantini","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy"},{"name":"UniCAMILLUS, International Medical University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-7284","authenticated-orcid":true,"given":"Francesco","family":"Fanfani","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-1195","authenticated-orcid":true,"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierandrea","family":"De Iaco","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-3720","authenticated-orcid":true,"given":"Vito","family":"Chiantera","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Universit\u00e0 di Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mandato","sequence":"additional","affiliation":[{"name":"Azienda Unit\u00e0 Sanitaria Locale-IRCCS, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6386-3565","authenticated-orcid":true,"given":"Giorgio","family":"Giorda","sequence":"additional","affiliation":[{"name":"Centro Riferimento Oncologico-IRCCS, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-5601","authenticated-orcid":true,"given":"Giovanni","family":"Aletti","sequence":"additional","affiliation":[{"name":"Istituto Europeo di Oncologia-IRCCS, Milan, Italy"},{"name":"Universit\u00e0 Statale degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Greggi","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori, Pascale-IRCCS, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Myriam","family":"Perrone","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1104-7866","authenticated-orcid":true,"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6556-5203","authenticated-orcid":true,"given":"Rita","family":"Trozzi","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-9041","authenticated-orcid":true,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000308"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00086-8"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001248"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_3_8_8_2","unstructured":"National Comprehensive Cancer Network: Ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer. https:\/\/www.nccn.org"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902626"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00006-1"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103294"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09226-7"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02085"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708618"},{"key":"e_1_3_8_15_2","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt JS","year":"1980","unstructured":"Spratt JS, Adcock RA, Muskovin M, et al: Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256-260, 1980","journal-title":"Cancer Res"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00370-5"},{"key":"e_1_3_8_17_2","volume-title":"Peritoneal Carcinomatosis: Principles of Management","author":"Sugarbaker PH","year":"1996","unstructured":"Sugarbaker PH (ed): Peritoneal Carcinomatosis: Principles of Management. Boston, MA, Kluwer Academic, 1996"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-5050-x"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.09.010"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4141-4"},{"key":"e_1_3_8_23_2","unstructured":"Cancer therapy evaluation program Common Terminology Criteria for Adverse Events version 4.0 DCTD NCI NIH DHHS. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34124"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00605"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0143"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.5510"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.24.00686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T23:00:14Z","timestamp":1740610814000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.24.00686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1200\/JCO.24.00686"],"URL":"https:\/\/doi.org\/10.1200\/jco.24.00686","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}